Dienogest

ATC Code G03DB08

Dienogest

Definition

An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma.

Also known as 17-Hydroxy-3-Oxo-19-Nor-17Alpha-Pregna-4,9-Diene-21-Nitrile, 19-Norpregna-4,9-Diene-21-Nitrile, 17-Hydroxy-3-Oxo-, (17Alpha)-, DIENOGEST, M 18575, MJR-35, STS 557, ZK 37659 — per NCIT

Also identified as

Indications

Disease Relation Source
Endometriosis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Female reproductive system may treat a disease of this organ DERIVED · CC BY 4.0
Genitourinary system may treat a disease of this organ DERIVED · CC BY 4.0
Reproductive system may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.